SK284495B6 - Spôsob výroby triazolyltryptamínových zlúčenín a medziprodukty na vykonávanie tohto spôsobu - Google Patents

Spôsob výroby triazolyltryptamínových zlúčenín a medziprodukty na vykonávanie tohto spôsobu Download PDF

Info

Publication number
SK284495B6
SK284495B6 SK1498-96A SK149896A SK284495B6 SK 284495 B6 SK284495 B6 SK 284495B6 SK 149896 A SK149896 A SK 149896A SK 284495 B6 SK284495 B6 SK 284495B6
Authority
SK
Slovakia
Prior art keywords
compound
formula
group
palladium
indol
Prior art date
Application number
SK1498-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK149896A3 (en
Inventor
Cheng Y. Chen
Robert D. Larsen
Thomas R. Verhoeven
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of SK149896A3 publication Critical patent/SK149896A3/sk
Publication of SK284495B6 publication Critical patent/SK284495B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Inorganic Insulating Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
SK1498-96A 1994-05-24 1995-05-19 Spôsob výroby triazolyltryptamínových zlúčenín a medziprodukty na vykonávanie tohto spôsobu SK284495B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine
PCT/US1995/005506 WO1995032197A1 (en) 1994-05-24 1995-05-19 Palladium catalyzed ring closure of triazolyl tryptamine

Publications (2)

Publication Number Publication Date
SK149896A3 SK149896A3 (en) 1997-09-10
SK284495B6 true SK284495B6 (sk) 2005-05-05

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1498-96A SK284495B6 (sk) 1994-05-24 1995-05-19 Spôsob výroby triazolyltryptamínových zlúčenín a medziprodukty na vykonávanie tohto spôsobu

Country Status (24)

Country Link
US (1) US5567824A (de)
EP (1) EP0763032B1 (de)
JP (1) JP3947216B2 (de)
KR (1) KR100385027B1 (de)
CN (2) CN1157390C (de)
AT (1) ATE252095T1 (de)
AU (1) AU688505B2 (de)
DE (1) DE69531939T2 (de)
DK (1) DK0763032T3 (de)
ES (1) ES2207648T3 (de)
FI (1) FI116899B (de)
HK (2) HK1009045A1 (de)
HR (1) HRP950304B1 (de)
HU (1) HU226460B1 (de)
MX (1) MX9605838A (de)
NZ (1) NZ285539A (de)
PT (1) PT763032E (de)
RO (1) RO118586B1 (de)
RU (1) RU2138496C1 (de)
SK (1) SK284495B6 (de)
TW (1) TW300221B (de)
UA (1) UA52586C2 (de)
WO (1) WO1995032197A1 (de)
YU (1) YU49345B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1997003068A1 (en) * 1995-07-11 1997-01-30 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
ES2185983T3 (es) * 1996-08-13 2003-05-01 Merck & Co Inc Indolizacion catalizada con paladio.
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
AU774829B2 (en) * 1999-06-28 2004-07-08 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
CA2552663A1 (en) 2004-01-09 2005-07-28 Ratiopharm Gmbh Crystalline forms of rizatriptan benzoate
WO2005075422A1 (en) * 2004-01-28 2005-08-18 Ratiopharm Gmbh Synthesis methods and intermediates for the manufacture of rizatriptan
PA8626701A1 (es) * 2004-03-26 2006-05-16 Wyeth Corp Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
EP1951713A1 (de) * 2005-11-14 2008-08-06 Matrix Laboratories Ltd Verfahren zur herstellung von rizatriptanbenzoat im grossmasstab
WO2007083320A2 (en) * 2006-01-19 2007-07-26 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
EP2160390A1 (de) * 2007-06-04 2010-03-10 Generics Ýuk¨Limited Neues verfahren
EP3407869A1 (de) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosale nanofaserträger zur therapeutischen behandlung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
HRP950304B1 (en) 2004-12-31
HU226460B1 (en) 2008-12-29
ATE252095T1 (de) 2003-11-15
CN1152920A (zh) 1997-06-25
EP0763032A1 (de) 1997-03-19
KR100385027B1 (ko) 2003-08-14
FI964669A0 (fi) 1996-11-22
AU688505B2 (en) 1998-03-12
FI964669A (fi) 1996-11-22
HUT76469A (en) 1997-09-29
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
HU9603236D0 (en) 1997-01-28
TW300221B (de) 1997-03-11
CN1157390C (zh) 2004-07-14
YU33495A (sh) 1998-07-10
KR970703336A (ko) 1997-07-03
NZ285539A (en) 1998-06-26
CN1077104C (zh) 2002-01-02
CN1322725A (zh) 2001-11-21
PT763032E (pt) 2004-02-27
US5567824A (en) 1996-10-22
WO1995032197A1 (en) 1995-11-30
FI116899B (fi) 2006-03-31
ES2207648T3 (es) 2004-06-01
JPH10500680A (ja) 1998-01-20
YU49345B (sh) 2005-07-19
HK1041262A1 (en) 2002-07-05
HK1041262B (zh) 2005-04-15
JP3947216B2 (ja) 2007-07-18
EP0763032B1 (de) 2003-10-15
RO118586B1 (ro) 2003-07-30
HK1009045A1 (en) 1999-05-21
DE69531939T2 (de) 2004-07-29
DK0763032T3 (da) 2004-02-09
DE69531939D1 (de) 2003-11-20
SK149896A3 (en) 1997-09-10
AU2467195A (en) 1995-12-18
MX9605838A (es) 1997-12-31
HRP950304A2 (en) 1997-08-31

Similar Documents

Publication Publication Date Title
SK284495B6 (sk) Spôsob výroby triazolyltryptamínových zlúčenín a medziprodukty na vykonávanie tohto spôsobu
JP2834889B2 (ja) テトラヒドロフラン抗真菌剤
KR100429754B1 (ko) 이미다졸 화합물 및 아데노신 데아미나아제 억제제로서의그의 용도
US5614524A (en) Piperazine derivatives as 5-HT1 Agonists
KR100214353B1 (ko) 불소 화합물
AU726027B2 (en) Quaternary ammonium compounds as tachykinin antagonists
KR20000023595A (ko) 1-치환 4-시아노-1,2,3-트리아졸의 제조방법
JP2965532B2 (ja) Ｎ−ベンジルアゾリウム誘導体
CZ296249B6 (cs) Zpusob výroby triazolyltryptaminového derivátu
JPH08283261A (ja) ３−フェニルトリアゾール誘導体および殺虫、殺ダニ剤
JP2896949B2 (ja) １−（４−アシルフェニル）アゾール類の製造方法
JP2961538B2 (ja) イミダゾロンおよびイミダゾリジノン誘導体の合成中間体および製造法
AU748710B2 (en) Imidazole compounds
WO1997017338A1 (en) Substituted 1-indolylpropyl-4-benzylpiperazine derivatives
SK12392003A3 (sk) Spôsob prípravy monohydrátu a kryštalických modifikácií flukonazolu
CA2313001A1 (en) Process for preparing triazole antimycotic compounds
EP1044192A1 (de) Verfahren zur herstellung von triazol derivaten
JP2001163892A (ja) アゾール誘導体又はその塩

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20100429

PC4A Assignment and transfer of rights

Owner name: SCHERING CORPORATION, KENILWORTH, NEW JERSEY, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121122

TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121122

MK4A Patent expired

Expiry date: 20150519